For instance, the blockade of CSF1R (using the monoclonal antibody AMG820) in combination with PD1 blocking antibody (Pembrolizumab) has been tested in clinical trials with colorectal cancer patients, although exhibiting a modest objective response rate of 6% (73). The gene discussed is CSF1R; the disease is colorectal cancer.